Published in Clinical Oncology Week, November 28th, 2005
According to researchers in Germany, "in the present study, we investigated the prognostic value of VEGF and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic NSCLC. From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were analyzed in 194 patients of a randomized phase III trial with enzyme-linked immunoassays."
"Patients with a VEGF serum level higher than the median serum level (10,995 pg/ml) had a significantly shorter overall survival than those with a lower serum level (p=.04). The MMP-9...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.